Refreshing results…
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
UploadIbrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
UploadA Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
UploadAcquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
UploadHCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Download from www.bloodjournal.orgIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Download from www.researchgate.netDiscovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
Download from doi.orgMissing publications? Search for publications with a matching author name.